OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc) and LinkedIn.
IOVaxis is an immunoncology company dedicated to research and development of neoantigen-based cancer immunotherapy including personalized therapeutic cancer vaccines. We are looking for clinical partners for our therapeutic cancer vaccines based on our “NeoCure” and “NeoReady” platforms.
Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.
Caprion Biosciences is a specialty laboratory CRO with an established track record in biomarkers, bioanalytical and immune monitoring services. Through its advanced immune monitoring platform, Caprion supports the development of vaccine and immunotherapy programs that require the characterization of innate and adaptive immunity… Read more
The Liberty PRIME is the absolute best system available for synthesizing peptides for personalized medicine. The system is cGMP compliant with unmatched purity, speed, and efficiency for peptide production in batch quantities. No other peptide synthesizer even comes close to the PRIME’s incredibly fast cycle times… Read more.
Pepscan is a provider for peptides and peptide-based services. With > 25 years of experience ranging from preparing complex peptide constructs to large peptide libraries. Preparing neoantigen peptides for personalized medicine routinely demands the highest level of care and reliability in terms of “within specs” and on-time delivery of these peptides to the patient…. Read More.
Ardigen provides technology platforms that leverage the power of Artificial Intelligence to increase the response rates in immuno-oncology. Our Neoepitope Prediction Platform focuses on recognizing truly immunogenic neoepitopes to enable therapeutic cancer vaccine design and development of T-cell based therapies. This computational solution aims to increase the effectiveness of neoantigen-based therapies and speed up the process of personalized treatment delivery.
Sanquin handles the blood supply in the Netherlands & is a centre of expertise in the field of blood, conducting scientific and clinical research in the fields of transfusion medicine, haematology and immunology. This knowledge is applied to development and manufacture of a variety of pharmaceutical products, diagnostic tests and services… Read more.